Search
Magaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Categories: Drugs for Acid Related DisordersClevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesProducts: Cleviprex 0,5 mg/ml Emulsion zur InjektionRipasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalto be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Endothelin Receptor Antagonists, Endothelin A Receptor AntagonistsLecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.
Tuberculin purified protein derivative
go.drugbank.com/drugs/DB11601ApprovedTuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis.
Ceftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnfor skin and skin structure infections and bacteremia in April 2024. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European
Anisindione
go.drugbank.com/drugs/DB01125ApprovedAnisindione is a synthetic anticoagulant and an indanedione derivative.
Synonyms: 2-p-Anisyl-1,3-indandione, 2-(p-Methoxyphenyl)-1,3-indandionePovidone K30
go.drugbank.com/drugs/DB14478ApprovedA polyvinyl polymer of variable molecular weight; used as suspending and dispersing agent and vehicle for pharmaceuticals; also used as blood volume expander. See [povidone] for full details.
Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates